Medy-Tox Inc.

KOSDAQ:A086900 Stock Report

Market Cap: ₩888.5b

Medy-Tox Valuation

Is A086900 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A086900 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A086900 (₩132000) is trading below our estimate of fair value (₩343015)

Significantly Below Fair Value: A086900 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A086900?

Key metric: As A086900 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A086900. This is calculated by dividing A086900's market cap by their current revenue.
What is A086900's PS Ratio?
PS Ratio3.6x
Sales₩246.25b
Market Cap₩888.53b

Price to Sales Ratio vs Peers

How does A086900's PS Ratio compare to its peers?

The above table shows the PS ratio for A086900 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average19.1x
A115450 HLB TherapeuticsLtd
13.1xn/a₩789.3b
A005250 Green Cross Holdings
0.3xn/a₩649.0b
A064550 Bioneer
1.7x23.5%₩515.9b
A007390 NatureCellLtd
61.2xn/a₩1.8t
A086900 Medy-Tox
3.6x12.5%₩888.5b

Price-To-Sales vs Peers: A086900 is good value based on its Price-To-Sales Ratio (3.6x) compared to the peer average (19.1x).

Price to Sales Ratio vs Industry

How does A086900's PS Ratio compare vs other companies in the KR Biotechs Industry?

27 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.8.7x33.7%
A086900 Medy-Tox
 3.6x12.5%US$636.19m
A006280 GC Biopharma
0.9x8.8%US$1.08b
A096530 Seegene
2.5x15.7%US$721.30m
A086900 3.6xIndustry Avg. 8.7xNo. of Companies27PS01632486480+
27 CompaniesEstimated GrowthMarket Cap
Industry Avg.8.7x65.5%
A086900 Medy-Tox
 3.6x68.1%US$636.19m
No more companies

Price-To-Sales vs Industry: A086900 is good value based on its Price-To-Sales Ratio (3.6x) compared to the KR Biotechs industry average (8.7x).

Price to Sales Ratio vs Fair Ratio

What is A086900's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A086900 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.6x
Fair PS Ratio3.2x

Price-To-Sales vs Fair Ratio: A086900 is expensive based on its Price-To-Sales Ratio (3.6x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A086900 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩132,000.00
₩210,000.00
+59.1%
14.3%₩260,000.00₩170,000.00n/a6
Nov ’25₩164,800.00
₩257,500.00
+56.3%
10.4%₩300,000.00₩230,000.00n/a4
Oct ’25₩192,400.00
₩257,500.00
+33.8%
10.4%₩300,000.00₩230,000.00n/a4
Sep ’25₩198,100.00
₩257,500.00
+30.0%
10.4%₩300,000.00₩230,000.00n/a4
Aug ’25₩173,000.00
₩276,000.00
+59.5%
31.4%₩390,000.00₩180,000.00n/a5
Jul ’25₩150,100.00
₩268,000.00
+78.5%
35.0%₩390,000.00₩170,000.00n/a5
Jun ’25₩130,600.00
₩296,000.00
+126.6%
33.5%₩390,000.00₩170,000.00n/a5
May ’25₩135,000.00
₩296,000.00
+119.3%
33.5%₩390,000.00₩170,000.00n/a5
Apr ’25₩147,000.00
₩296,000.00
+101.4%
33.5%₩390,000.00₩170,000.00n/a5
Mar ’25₩158,000.00
₩318,333.33
+101.5%
19.8%₩390,000.00₩220,000.00n/a6
Feb ’25₩190,400.00
₩328,333.33
+72.4%
22.6%₩430,000.00₩220,000.00n/a6
Jan ’25₩241,000.00
₩335,000.00
+39.0%
24.2%₩430,000.00₩220,000.00n/a6
Dec ’24₩222,500.00
₩335,000.00
+50.6%
24.2%₩430,000.00₩220,000.00n/a6
Nov ’24₩205,500.00
₩350,000.00
+70.3%
23.1%₩430,000.00₩220,000.00₩164,800.005
Oct ’24₩252,500.00
₩345,000.00
+36.6%
26.0%₩430,000.00₩220,000.00₩192,400.004
Sep ’24₩251,000.00
₩332,500.00
+32.5%
24.0%₩430,000.00₩220,000.00₩198,100.004
Aug ’24₩216,000.00
₩330,000.00
+52.8%
22.2%₩410,000.00₩220,000.00₩173,000.004
Jul ’24₩235,500.00
₩291,800.00
+23.9%
34.5%₩410,000.00₩139,000.00₩150,100.005
Jun ’24₩261,000.00
₩263,800.00
+1.1%
33.6%₩410,000.00₩139,000.00₩130,600.005
May ’24₩236,000.00
₩234,126.98
-0.8%
30.8%₩290,000.00₩132,380.95₩135,000.003
Apr ’24₩221,500.00
₩194,126.98
-12.4%
32.3%₩280,000.00₩132,380.95₩147,000.003
Mar ’24₩218,500.00
₩177,428.57
-18.8%
32.6%₩280,000.00₩114,285.71₩158,000.005
Feb ’24₩137,100.00
₩138,428.57
+1.0%
20.1%₩190,476.19₩114,285.71₩190,400.005
Jan ’24₩128,000.00
₩134,724.13
+5.3%
20.3%₩190,476.19₩109,523.81₩241,000.006
Dec ’23₩113,047.62
₩135,714.29
+20.1%
19.8%₩190,476.19₩109,523.81₩222,500.006
Nov ’23₩100,952.38
₩131,746.03
+30.5%
20.2%₩180,952.38₩95,238.10₩205,500.006

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩282,000.00

7D

6.8%

1Y

76.9%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,210.00

7D

-5.0%

1Y

n/a

Ildong Pharmaceutical

₩343.6b

Develops, manufactures, and sells pharmaceutical products in South Korea.

A249420

₩12,380.00

7D

0.7%

1Y

-25.2%